Biotech Startups

Libra Therapeutics develops small molecule therapeutics targeting lysosomal function and autophagy to treat neurodegenerative diseases including ALS, Parkinson's, Alzheimer's, and Huntington's disease. The company's approach aims to restore cellular balance by enhancing the body's natural ability to clear toxic proteins and dysfunctional organelles.

2 investors

Lifebit develops enterprise data platforms for organizations with genomic and biomedical datasets, enabling researchers to analyze distributed data in-situ without moving sensitive information. The company serves therapeutic and research organizations seeking to unlock insights from siloed biomedical data.

2 investors

LifeDNA produces DNA-targeted supplements formulated based on genetic data to support specific health outcomes. The company offers personalized wellness products including sleep support and methylation support formulas for individual customers.

2 investors

Lifespin combines nuclear magnetic resonance spectroscopy (NMR) and AI to turn metabolites in a small blood sample into digital metabolic profiles used for prevention, early diagnosis, and therapy monitoring. It serves individuals and clinical medicine with metabolomic health assessments drawing on a proprietary database of 275,000+ human datasets.

2 investors

Lighten builds technology infrastructure to enable healthcare organizations to leverage clinical data for drug discovery, personalized treatment insights, and therapy adoption. The company combines AI and data infrastructure with clinical expertise embedded in product design.

2 investors

Lighthouse Pharmaceuticals develops precision therapeutics for major unmet medical needs, with a lead program (LHP588), a gingipain inhibitor being tested in the Phase 2 SPRING trial for P. gingivalis-positive Alzheimer's disease. The company works in the biotechnology and drug development space, using patient responder analyses and dose modeling to advance its clinical candidates.

2 investors

Lilac develops biological seed inoculants for legume crops, with PL11 designed to enhance nitrogen fixation and yield for yellow pea and lentil growers in the Northern Plains through engineered Rhizobium strains.

2 investors

Liminal BioSciences, through subsidiary CALEDON BIOSCIENCE, discovers and develops small molecule therapeutics targeting G protein-coupled receptor pathways for metabolic, inflammatory, and fibrotic diseases. The company applies drug discovery and medicinal chemistry expertise to create novel therapeutic candidates in underexplored GPCR pathways.

2 investors

Lindy Biosciences develops biotherapeutic drug delivery technology using a proprietary Microglassification platform to reformulate antibody therapeutics into forms patients can self-administer at home instead of via intravenous infusion. It partners with pharmaceutical companies developing biotherapeutic drug products.

2 investors

Lineagen provides genetic testing and optical genome mapping services for clinical diagnosis and research applications. The company offers laboratory analysis to identify structural variations and genetic answers for medical and research purposes.

2 investors

Linear Diagnostics develops near-patient (point-of-care) diagnostic technology using EXPAR that delivers results in under 15 minutes, initially focused on detecting sexually transmitted infections and other infectious diseases. Its rapid testing is aimed at STI clinics to enable immediate treatment and reduce onward transmission.

2 investors

LinusBio develops precision medicine diagnostics based on exposome sequencing to identify biomarkers for complex conditions including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, and other diseases. The company serves physicians and patients seeking earlier detection and intervention for conditions that historically lacked molecular diagnostic endpoints.

2 investors

Lir develops AI-driven viral vector engineering for gene therapy, using machine learning to optimize AAV (adeno-associated virus) vectors for improved dose efficiency, tissue targeting, and immune evasion.

2 investors

Living Models builds foundation models for biology, working at the intersection of AI and life sciences. Its team consists of PhDs and engineers with backgrounds from research and technology organizations.

2 investors

Lixa develops NeoX, an antimicrobial technology targeting antibiotic-resistant bacteria and biofilm fouling across pharmaceutical, industrial, food, and agricultural sectors. The company addresses antimicrobial resistance through a single mechanism that operates across multiple markets with multiple licensing pathways.

2 investors

LogicFlo builds task-specialized AI agents organized into coordinated "desks" (research, writing, review) that handle medical affairs and scientific content work such as MSL decks, manuscripts, literature reviews, and MLR-ready content for life sciences and biopharma teams. The platform integrates with enterprise systems like Veeva and SharePoint and is built for regulated environments with SOC 2, ISO 27001, and HIPAA compliance.

2 investors

Longenesis operates a platform for health and biomedical data management used to run research studies, including managing study participants across the Baltics and Mediterranean regions. It partners with genomics providers to offer services such as whole genome sequencing to study participants.

2 investors

Longeveron is a clinical-stage biotechnology company developing allogeneic cellular therapies for life-threatening conditions affecting children and the elderly. Its investigational candidate is being evaluated for indications including Hypoplastic Left Heart Syndrome, Pediatric Dilated Cardiomyopathy, Alzheimer's Disease, and age-related frailty.

2 investors

A venture capital firm focused on the longevity sector, backing founder-driven companies working on extending human healthy lifespan. It runs investment funds and an accelerator for longevity startups, and has backed some of the first longevity companies to reach IPO and bring drug candidates to market.

2 investors

Loopworm produces custom recombinant proteins—antigens, antibodies, cytokines, growth factors and enzymes—by using living silkworms as bioreactors instead of stainless-steel fermenters or mammalian cell culture. It serves human and animal therapeutics, diagnostics, biotech research and industrial applications, and is based in Bengaluru, India.

2 investors

2 investors

LSK Technologies builds a portable distributed testing platform for diagnosing infectious diseases in field and remote settings. The device, called PLUM, enables rapid and decentralized diagnostic testing for pathogens like Zika virus and SARS-CoV-2.

2 investors

EQT Life Sciences (formerly LSP) is one of Europe's largest life sciences investment firms that invests in innovative companies developing therapeutics, medical devices, diagnostics, and healthtech solutions. The firm targets companies with the potential to address unmet clinical needs and improve patient outcomes, with a 30-year track record and approximately 3.5 billion euros raised across multiple funds.

2 investors

Lubricin (PRG4) is a glycoprotein found naturally in the human body that lubricates and protects tissue surfaces from friction and wear. The company develops recombinant lubricin as a therapeutic agent to address inflammation-related conditions like dry eye and osteoarthritis.

2 investors